Nektar Therapeutics (NKTR) Shares Declined While Camber Capital Management Decreased Its Stake by $196.10 Million; Garrison Cap (GARS) Market Valuation Rose While Caxton Lifted Stake by $920,576

August 10, 2018 - By Victoria Pittman

Nektar Therapeutics (NASDAQ:NKTR) Logo

Caxton Corp increased its stake in Garrison Cap Inc (GARS) by 11.51% based on its latest 2018Q1 regulatory filing with the SEC. Caxton Corp bought 115,072 shares as the company’s stock rose 9.02% while stock markets declined. The institutional investor held 1.12M shares of the company at the end of 2018Q1, valued at $9.05 million, up from 1.00M at the end of the previous reported quarter. Caxton Corp who had been investing in Garrison Cap Inc for a number of months, seems to be bullish on the $135.30 million market cap company. The stock increased 0.60% or $0.05 during the last trading session, reaching $8.43. About 17,800 shares traded. Garrison Capital Inc. (NASDAQ:GARS) has declined 0.34% since August 10, 2017 and is downtrending. It has underperformed by 12.91% the S&P500. Some Historical GARS News: 01/05/2018 – Indian Motorcycle & Carey Hart Bring V-Twin-Powered Armed Forces Day Celebration to Troops at U.S. Army Garrison Stuttgart; 26/04/2018 – Sen. Roy Blunt: Blunt Statement on Confirmation of Timothy Garrison to Serve as U.S. Attorney for the Western District of; 17/04/2018 – Garrison Capital Inc. Schedules Earnings Release for the First Quarter Ended March 31, 2018; 06/03/2018 – Garrison Capital 4Q EPS 23c; 06/03/2018 – GARRISON CAPITAL INC QTRLY NET INVESTMENT INCOME PER SHARE $0.27; 10/05/2018 – Metalla Announces Friendly Acquisition of Valgold and Royalty on the Garrison Project; 24/05/2018 – Former President of Arm Holdings, Tudor Brown, to Join Board of Garrison Technology; 06/03/2018 Garrison Capital Inc. Declares First Quarter 2018 Distribution of $0.28 Per Share and Announces Fourth Quarter and Fiscal Year; 06/03/2018 – GARRISON CAPITAL INC QTRLY NET EARNINGS PER SHARE $0.23; 10/05/2018 – Heninger Garrison Davis, LLC Files Class Action Against the United States Patent and Trademark Office For “Taking”

Camber Capital Management Llc decreased its stake in Nektar Therapeutics (NKTR) by 55.22% based on its latest 2018Q1 regulatory filing with the SEC. Camber Capital Management Llc sold 1.85M shares as the company’s stock declined 11.70% with the market. The hedge fund held 1.50 million shares of the major pharmaceuticals company at the end of 2018Q1, valued at $159.39M, down from 3.35M at the end of the previous reported quarter. Camber Capital Management Llc who had been investing in Nektar Therapeutics for a number of months, seems to be less bullish one the $10.18B market cap company. The stock increased 6.09% or $3.41 during the last trading session, reaching $59.37. About 4.86M shares traded or 12.59% up from the average. Nektar Therapeutics (NASDAQ:NKTR) has risen 271.91% since August 10, 2017 and is uptrending. It has outperformed by 259.34% the S&P500. Some Historical NKTR News: 11/05/2018 – Nektar Presenting at Conference Jun 4; 08/03/2018 – REG-Bavarian Nordic Announces Phase 2 Trial Investigating Combination of Its Immunotherapy CV301 and Nivolumab in Microsatellite Stable Colorectal Cancer; 26/03/2018 – Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo Four-Week Dosing Schedule for Advanced; 25/04/2018 – EC OKS BMY’S OPDIVO FOUR-WEEK DOSING FOR ADVANCED MELANOMA; 25/03/2018 – ONO: OPDIVO APPROVED FOR WIDER USE IN HODGKIN LYMPHOMA IN KOREA; 16/04/2018 – U.S. Food and Drug Administration Approves Opdivo® (nivolumab) + Yervoy® (ipilimumab) Combination as First-Line Treatment for; 13/04/2018 – OPDIVO (NIVOLUMAB), FIRST PD-1 INHIBITOR TO DEMONSTRATE SUPERIOR SURVIVAL BENEFIT COMPARED WITH CHEMOTHERAPY IN A PREDOMINANTLY CHINESE POPULATION WITH PREVIOUSLY TREATED NON-SMALL CELL LUNG CANCE…; 06/03/2018 – BRISTOL-MYERS SQUIBB – OPDIVO ALSO WAS APPROVED FOR A SHORTER 30-MINUTE INFUSION ACROSS ALL APPROVED INDICATIONS; 10/05/2018 – Nektar Therapeutics 1Q Loss/Shr 60c; 11/04/2018 – NEKTAR NKTR-262 COMBO HAD COMPLETE REGRESSIONS IN MOUSE MODELS

Investors sentiment increased to 1.75 in Q1 2018. Its up 0.58, from 1.17 in 2017Q4. It is positive, as 1 investors sold GARS shares while 7 reduced holdings. 4 funds opened positions while 10 raised stakes. 3.72 million shares or 3.98% more from 3.57 million shares in 2017Q4 were reported. Blair William & Com Il reported 28,500 shares or 0% of all its holdings. Stephens Ar accumulated 25,484 shares. Wells Fargo And Mn stated it has 9,320 shares or 0% of all its holdings. Ares Mgmt Ltd Liability Corp accumulated 0.03% or 116,970 shares. Great West Life Assurance Com Can has invested 0% in Garrison Capital Inc. (NASDAQ:GARS). Hudock Group Ltd has 650 shares. Moreover, Royal Bancorp Of Canada has 0% invested in Garrison Capital Inc. (NASDAQ:GARS) for 2,000 shares. Tower Research Cap Llc (Trc) has invested 0% in Garrison Capital Inc. (NASDAQ:GARS). Jpmorgan Chase And has 0% invested in Garrison Capital Inc. (NASDAQ:GARS) for 24,921 shares. D E Shaw And reported 10,359 shares. Drw Securities Ltd Liability Corp reported 0.23% stake. Ajo Lp reported 99,171 shares. Morgan Stanley reported 33,306 shares or 0% of all its holdings. Manufacturers Life Insurance The has invested 0% of its portfolio in Garrison Capital Inc. (NASDAQ:GARS). Oppenheimer & Incorporated has invested 0.01% in Garrison Capital Inc. (NASDAQ:GARS).

Another recent and important Garrison Capital Inc. (NASDAQ:GARS) news was published by Nasdaq.com which published an article titled: “Garrison Capital Inc. Schedules Earnings Release for the Second Quarter Ended June 30, 2018” on July 17, 2018.

Caxton Corp, which manages about $85.88 million US Long portfolio, decreased its stake in Strongbridge Biopharma Plc by 138,955 shares to 5.38M shares, valued at $47.31M in 2018Q1, according to the filing.

Among 6 analysts covering Garrison Capital (NASDAQ:GARS), 2 have Buy rating, 0 Sell and 4 Hold. Therefore 33% are positive. Garrison Capital had 17 analyst reports since August 5, 2015 according to SRatingsIntel. The rating was maintained by National Securities on Wednesday, August 5 with “Buy”. The firm has “Neutral” rating by Ladenburg Thalmann given on Friday, November 6. The stock has “Buy” rating by Zacks on Wednesday, August 5. The firm has “Buy” rating given on Friday, March 9 by Maxim Group. The firm has “Hold” rating given on Thursday, March 16 by Wunderlich. As per Thursday, November 9, the company rating was maintained by Maxim Group. The company was maintained on Thursday, March 17 by Stephens. The rating was upgraded by Zacks to “Hold” on Tuesday, August 11. Maxim Group maintained the stock with “Buy” rating in Monday, August 10 report. The stock of Garrison Capital Inc. (NASDAQ:GARS) earned “Buy” rating by Maxim Group on Thursday, August 10.

Since February 16, 2018, it had 1 buy, and 33 selling transactions for $89.16 million activity. 10,000 shares were sold by GREER R SCOTT, worth $602,786. Shares for $410,029 were sold by Nicholson John. $14.89 million worth of Nektar Therapeutics (NASDAQ:NKTR) was sold by Doberstein Stephen K on Friday, April 6. ROBIN HOWARD W had sold 130,000 shares worth $6.44 million. 90,000 shares were sold by Labrucherie Gil M, worth $7.56M on Tuesday, May 1. WHITFIELD ROY A bought 5,000 shares worth $290,212.

Camber Capital Management Llc, which manages about $1.75 billion and $2.04 billion US Long portfolio, upped its stake in Allergan Plc by 250,000 shares to 850,000 shares, valued at $143.05M in 2018Q1, according to the filing. It also increased its holding in Tesaro Inc (NASDAQ:TSRO) by 875,000 shares in the quarter, for a total of 1.73M shares, and has risen its stake in Endologix Inc (NASDAQ:ELGX).

Among 13 analysts covering Nektar Therapeutics (NASDAQ:NKTR), 12 have Buy rating, 0 Sell and 1 Hold. Therefore 92% are positive. Nektar Therapeutics had 33 analyst reports since August 6, 2015 according to SRatingsIntel. PiperJaffray maintained the shares of NKTR in report on Friday, April 13 with “Overweight” rating. On Monday, April 9 the stock rating was maintained by Cowen & Co with “Buy”. Piper Jaffray maintained the shares of NKTR in report on Thursday, January 7 with “Overweight” rating. Mizuho maintained the shares of NKTR in report on Thursday, March 29 with “Buy” rating. Roth Capital maintained the stock with “Buy” rating in Thursday, July 20 report. The company was maintained on Tuesday, June 5 by Canaccord Genuity. On Wednesday, November 8 the stock rating was maintained by Jefferies with “Buy”. H.C. Wainwright reinitiated it with “Buy” rating and $125 target in Monday, April 2 report. As per Monday, June 4, the company rating was maintained by JP Morgan. The firm earned “Buy” rating on Tuesday, July 18 by J.P. Morgan.

Garrison Capital Inc. (NASDAQ:GARS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts